Pentamer List | ProImmune

Introduction to Pentamers

Pentamer Handbook

Custom Pro5® Pentamers

Pentamer Applications

Technical Webcasts about Pro5® Pentamers

Customer Testimonials

Pentamer Publications

Pentamer Case Studies

Request Quote

Catalog Pro5® MHC Class I Pentamers

Pentamers by Research Area

AAV HIV/SIV Minor Histocompatibility Antigen Trypanosoma
Adenovirus HPV Model Antigen Tuberculosis
Autoimmunity HSV MuLV Vaccinia
Cancer HTLV Negative Varicella Zoster Virus
Chlamydia Influenza Other VSV
CMV JC Virus RSV West Nile Virus
EBV LCMV Sendai Virus Yellow Fever Virus
HBV Listeria SV40 Virus  
HCV Malaria Toxoplasma gondii  

 

S = Stock Item - dispatched approximately 1-2 days from receipt of order

A = Available Item - dispatched approximately 1-2 weeks from receipt of order

 

AAV

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 886 SADNNNSEY A AAV VP1 492-500
B*07:02 651 VPQYGYLTL A AAV2 372-380

 

Adenovirus


Publications citing Adenovirus Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 686 TDLGQNLLY A Adenovirus 5 Hexon 886-894
A*24:02 684 TYFSLNNKF A Adenovirus 5 Hexon 37-45
B*07:02 989 KPYSGTAYNAL A Adenovirus Hexon 114-124
B*07:02 685 KPYSGTAYNSL A AdV Hexon
B*35:01 1346 IPYLDGTFY A AdV Hexon
H-2Db 2206 SGPSNTPPEI A Ad5 E1A  234–243

 

Autoimmunity


Publications citing AutoImmunity Pentamers
Case studies of Customer Research into AutoImmunity

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 151 KLQVFLIVL A T1D Diabetes human prepro islet amyloid polypeptide ppIAPP 5-13
A*02:01 954 LNIDLLWSV A T1D Diabetes IGRP 228–236
A*02:01 851 HLVEALYLV A Insulin B chain 10-18
A*02:01 393 VMNILLQYV A GAD65 114-123
A*02:01 470 SLSRFSWGA A Myelin basic protein 110-118
A*02:01 1904 VLFGLGFAI A T1D Diabetes IGRP 265-273
A*02:01 2259 ALWGPDPAAA A Proinsulin precursor 15-24
A*02:01 3342 YTCPLCRAPV A SSA SS-56 55-64
A*02:01 2382 MVWESGCTV A IA-2 797-805
A*02:01 3394 VIVMLTPLV A IA-2 805-813
H-2Db 1107 RSPFSRVVHL A MOG Precursor 69-78

 

(back to top)

 

Cancer


Publications Citing Cancer Pentamers
Case Studies of Customer Research into Cancer

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 307 KSDICTDEY A Tyrosinase 243-251 (244S)
A*01:01 029 EADPTGHSY A MAGE-A1 161-169
A*01:01 030 EVDPIGHLY A MAGE-A3 168-176
A*01:01 3383 TLDTLTAFY A Mesothelin 429-437
A*02:01 086 ALQPGTALL S Prostate Stem Cell Antigen (PSCA) 14-22
A*02:01 082 ELAGIGILTV S MelanA / MART 26-35
A*02:01 404 FLTPKKLQCV A Prostate Specific Antigen-1 (PSA-1) 141-150
A*02:01 389 GLYDGMEHL A MAGEA-10 254-262
A*02:01 125 GVLVGVALI A Carcinogenic Embryonic Antigen (CEA) 694-702
A*02:01 249 HLSTAFARV A G250 (renal cell carcinoma) 217-225
A*02:01 085 ILAKFLHWL S Telomerase 540-548
A*02:01 210 ILHNGAYSL A HER-2/neu 435-443
A*02:01 046 IMDQVPFSV S gp100 (pmel17) 209-217
A*02:01 214 KIFGSLAFL S HER-2/neu 369-377
A*02:01 057 KTWGQYWQV A gp100 (pmel17) 154-162
A*02:01 302 KVAELVHFL A MAGEA3 112-120
A*02:01 171 KVLEYVIKV A MAGEA1 278-286
A*02:01 205 LLGRNSFEV A p53 264-272
A*02:01 208 LLLLTVLTV A MUC-1 12-20
A*02:01 212 RLLQETELV S HER-2/neu 689-697
A*02:01 390 SLLMWITQV A NY-ESO-1 157-165
A*02:01 097 VISNDVCAQV A Prostate Specific Antigen-1 (PSA-1) 154-163
A*02:01 250 VLQELNVTV S Leukocyte Proteinase-3 (Wegener's autoantigen) 169-177
A*02:01 157 VLYRYGSFSV A gp100 (pmel17) 476-485
A*02:01 075 YLSGANLNL S Carcinogenic Embryonic Antigen (CEA) 571-579
A*02:01 391 LMLGEFLKL S Survivin 96-104
A*02:01 781 VLDGLDVLL A PRAME 100-108
A*02:01 34 FLWGPRALV A MAGEA3 271-279
A*02:01 394 YLFFYRKSV A mTERT 572-580
A*02:01 599 ALDVYNGLL A Prostatic acid phosphatase precursor (PAP) 299-307
A*02:01 600 ALFDIESKV A PSM P2 (prostate)
A*02:01 405 KLQCVDLHV A Prostate Specific Antigen 146-154
A*02:01 527 ALYVDSLFFL A PRAME PRA 300–309
A*02:01 1013 FLGYLILGV A Prostatic Acid Phosphatase-3 (PAP-3)
A*02:01 813 FVGEFFTDV A GPC3 144-152 (overexpressed in hepatocellular carcinoma)
A*02:01 560 GLMEEMSAL A Human Mena protein (overexpressed in breast cancer)
A*02:01 329 ILLWQPIPV A Prostatic Acid Phosphatase-3 (PAP-3) 135-143
A*02:01 646 KLFGTSGQKT A EGF-R-479 350-359
A*02:01 859 KLQDASAEV A HM1.24-aa 126-134
A*02:01 810 LIAHNQVRQV A HER-2/neu (85–94)
A*02:01 690 LLHETDSAV A PSMA/PSM-P1 4-12
A*02:01 338 QLCPICRAPV A Livin/ML-IAP280 175-184
A*02:01 117 RLVDDFLLV A Telomerase Reverse Transcriptase  865-873
A*02:01 1056 SLFLGILSV A CD20 188-196 (B cell malignancies)
A*02:01 1181 SLSEKTVLL A CD59 glycoprotein precursor 106-114
A*02:01 958 SLVDVMPWL A Cytochrome p450 1B1 239-248
A*02:01 915 TLPGYPPHV A PAX-5 311-319
A*02:01 561 TMNGSKSPV A hMena 502-510
A*02:01 689 VLAGGFFLL A PSMA 27-38 
A*02:01 645 YLNTVQPTCV A EGF-R 1138-1147
A*02:01 447 YLQVNSLQTV A Telomerase Reverse Transcriptase (hTRT) 988-997
A*02:01 1403 VIMPCSWWV A Chondromodulin-I 319-327
A*02:01 2079 FLYDDNQRV A Topoisomerase II-alpha-b 828-836
A*02:01 2083 FLAEDALNTV A Epithelial Discoidin Domain Receptor 1 (EDDR1) 867-876
A*02:01 061 YMDGTMSQV A Tyrosinase 369-377 (371D)
A*02:01 468 ILSLELMKL A Receptor for hyaluronic acid–mediated
motility (RHAMM) 165-173
A*02:01 1201 YMCSFLFNL A Ewing Tumor EZH2 666-674
A*02:01 1386 GLAPPQHLIRV A p53 187-197
A*02:01 1464 LTLGEFLKL A Survivin-3A 96-104
A*02:01 1920 ALLTSRLRFI A Telomerase Reverse Transcriptase (hTRT) 615-624
A*02:01 2291 AILALLPAL A Prostate Stem Cell Antigen (PSCA) 105-133
A*02:01 2299 SLPPPGTRV A p53 149-157 
A*02:01 2293 GLQHWVPEL A BA46 (Lactadherin) 97-106
A*02:01 1786 GLLGASVLGL A Telomerase Reverse Transcriptase (hTRT) 674-683
A*02:01 2294 GVRGRVEEI A BCR-ABL
A*02:01 2296 ITDQVPFSV A gp100 (pmel) 209-217
A*02:01 2297 KLCPVQLWV A p53 139-147 
A*02:01 2298 KVAEELVHFL A MAGEA3 112-120 (alternative version)
A*02:01 381 LLLTVLTVV A Tumor Mucin Antigen 13-21
A*02:01 654 RMPEAAPPV A p53 65-73
A*02:01 049 SLLMWITQC A NY-ESO-1 157-165 (9C)
A*02:01 047 YLEPGPVTV A gp100 (pmel) 280-288 (288V)
A*02:01 2300 YLGSYGFRL A p53 103-111 
A*02:01 2301 YLQLVFGIEV A MAGEA2 157-166
A*02:01 048 YLSGADLNL A Carcinoembryonic antigen (CEA)-derived peptide CAP1-6D
A*02:01 773 VLPLTVAEV A Mesothelin 530–538 
A*02:01 860 SLYSFPEPEA A PRAME
A*02:01 1509 TLADFDPRV A EphA2
A*02:01 893 VLDFAPPGA A WT1
A*02:01 861 SLLQHLIGL A PRAME 425-433
A*02:01 058 YLEPGPVTA A gp100
A*02:01 163 FMNKFIYEI A Human alfa fetoprotein 158-166
A*02:01 2988 RVA(PHOSPHO-S)PTSGV A Insulin receptor substrate-2 1097-1105
A*02:01 841 LLLIWFRPV A BKV Ltag 579-587
A*02:01 862 VIFDFLHCI A BKV Ltag 406-414
A*02:01 2103 YMLDLQPET A E7 11-19
A*02:01 400 ELTLGEFLKL A survivin 95-104
A*02:01 575 GVYDGREHTV A MAGE-A4 230–239
A*02:01 1421 KVVEFLAML A MAGE-C1 1083-1091
A*02:01 780 QLFEELQEL A Heme oxygenase-1 212-220
A*02:01 2990 RVASPTSGV A IRS-2 1097-1105
A*02:01 464 YMNGTMSQV A Tyrosinase 368-376
A*02:01 1778 ALMEQQHYV A ITGB8 662-670
A*02:01 3343 ALNVYNGLL A ACPP 299-307
A*02:01 1508 ALPFGFILV A IL13R 345-353
A*02:01 3344 ALSPVPPVV A Bcl-2 85-93
A*02:01 3345 ALVCYGPGI A FAP alpha 463-471
A*02:01 3346 ALWPWLLMAT A RNF43 11-20
A*02:01 3347 ALYLMELTM A CB9L2
A*02:01 3350 CLPSPSTPV A BMI1 271-279
A*02:01 3352 ELSDSLGPV A PASD1 695-703
A*02:01 3355 FLFLRNFSL A TARP(V28L)27-35
A*02:01 3356 FLPSPLFFFL A TARP(P5L) 5-13
A*02:01 3357 GLFKCGIAV A FAP 639-647
A*02:01 3358 GLIQLVEGV A TRAG-3 4-12
A*02:01 3361 ILGVLTSLV A DLK1 309-317
A*02:01 811 ILHDGAYSL A HER-2 434-443
A*02:01 3363 LLVPTCVFLV A 691-700
A*02:01 3365 MLAVFLPIV A STEAP 292-300 (293L)
A*02:01 3366 NLFETPVEA A 194-202
A*02:01 480 PLFDFSWLSL A Bcl-2 208-217
A*02:01 3368 QLGEQCWTV A PSCA 44-51 (51A)
A*02:01 1908 QLLDGFMITL A PASD1 39-48
A*02:01 3371 RLAEYQAYI A SART3 309-317
A*02:01 1937 RLSSCVPVA A 131-139
A*02:01 202A RMFPNAPYL A WT-1 126-134 (Wilms tumor)
A*02:01 3374 SIDWFMVTV A p31-39
A*02:01 3375 SILLRDAGLV A TRAG-3 57-66
A*02:01 3377 SLFEPPPPG A PSMA 85-93
A*02:01 452 SLGEQQYSV A WT1 187-195
A*02:01 774 SLLFLLFSL A 20-28
A*02:01 3379 SQADALKYV A EZH2 729-737
A*02:01 2371 TLQDIVYKL A BMI1 74-82
A*02:01 3386 WLSLKTLLSL A Bcl-2 214-223
A*02:01 2081 YLIELIDRV A TACE 250-258
A*02:01 1239 YLISGDSPV A CD33 65-73 (1Y2L)
A*02:01 594 YLNDHLEPWI A Bcl-X 173-182
A*02:01 3387 YLNRHLHTWI A BCL-2 180-189
A*02:01 3388 YLQWIEFSI A Prominin1 744-752
A*02:01 1910 YLVGNVCIL A PASD1 168-176
A*02:01 3389 YLYQWLGAPV A Osteocalcin 51-60
A*02:01 3416 KLMSSNSTDL A HSP105 234-243
A*02:01 960 RLMNDMTAV A HSP105 128-136
A*02:01 884 RLWQELSDI A circadian clock protein PASD1 691-700
A*02:01 628 LLAARAIVAI A iLR1 59-68
A*02:01 2282 FLDPRPLTV A CYP190
A*02:01 543 ALCNTDSPL A iLR1
A*02:01 1303 LLFGLALIEV A MAGE-C2 191-200
A*02:01 550 ALKDVEERV A MAGE-C2 336-344
A*02:01 3418 STLCQVEPV A MPP11
A*02:01 3419 VLQMKEEDV A iLR1
A*02:01 3420 AIQDLCLAV A NPM1
A*02:01 3421 QLLIKAVNL A MPP11
A*02:01 3422 AIQDLCVAV A NPM1
A*02:01 3423 ALTPVVVTL A cyclin-dependent kinase 4 170-178
A*03:01 118 ALLAVGATK A gp100 (pmel17) 17-25
A*03:01 264 ATGFKQSSK A bcr-abl 210 kD fusion protein 259-269
A*03:01 087 KQSSKALQR S bcr-abl 210 kD fusion protein 21-29
A*03:01 541 RISTFKNWPK A Survivin-3A 18-27 (27K)
A*03:01 3369 QVLKKIAQK A HMOX1 145-153
A*03:01 3370 RIAAWMATY A 165-173
A*03:01 552 RLGLQVRKNK A RhoC 176-185 (177L)
A*03:01 615 RLLFFAPTR A Mcl-1 95-103
A*24:02 230 AFLPWHRLF A Tyrosinase 188-196
A*24:02 416 EYLQLVFGI A MAGEA2 156-164
A*24:02 421 TFPDLESEF A MAGEA3 97-105
A*24:02 209 TYACFVSNL A Carcinogenic Embryonic Antigen (CEA) 652-660
A*24:02 417 TYLPTNASL A HER-2/neu 63-71
A*24:02 418 VYGFVRACL A Telomerase reverse transcriptase (hTRT) 461-469
A*24:02 238 VYFFLPDHL A gp100-intron 4  (170-178)
A*24:02 2303 CYASGWGSI A Prostate Specific Antigen-1 153-161
A*24:02 2302 AYACNTSTL A Survivin 80-88
A*24:02 1806 RYCNLEGPPI A Lymphocyte antigen 6 complex locus K (LY6K) 177-186
A*24:02 237 IMPKAGLLI A MAGE-A3
A*24:02 3351 DYLNEWGSRF A CDH3 807-816
A*24:02 1064 DYLQYVLQI A MiHA ACC1 15-23
A*24:02 3353 EYCPGGNLF A MELK 87-95 (93N)
A*24:02 3380 EYRALQLHL A CA9 219-227
A*24:02 3354 EYYELFVNI A DEP DC1 294-302
A*24:02 3360 GYCTQIGIF A HENMT1 221-229
A*24:02 3362 IYTWIEDHF A FOXM1 262-270
A*24:02 3367 NYQPVWLCL A RNF43 721-729 (722Y)
A*24:02 3372 RYNAQCQETI A Midkine 110-119
A*24:02 3382 SYRNEIAYL A TTK protein kinase 551-559
A*24:02 3384 VYLRVRPLL A KIF20A 67-75
A*24:02 3385 VYYNWQYLL A IL13r 146-154
A*29:02 3397 KEKYIDQEEL A HSP90 alpha 280-288 (Pathologic Conditions)
A*68:01 3398 TVSGNILTIR A NY-ESO-1 127-136
B*07:02 2304 LPWHRLFLL A Tyrosinase 208-216
B*07:02 3239 TPNQRQNVC A P2X5
B*07:02 2369 EPR(PHOSPHO-S)PSHSM A Insulin receptor substrate 2
B*07:02 3348 APRGVRMAV A LAGE-1 46-54
B*07:02 3364 LPVSPRLQL A CEACAM 185-193
B*07:02 3378 SPFFLLLLL A Tumor Mucin antigen 7-15
B*08:01 094 GFKQSSKAL A bcr-abl 210 kD fusion protein 19-27
B*27:05 424 GRFGLATEK A BRAF 594-601 (600E)
B*27:05 3359 GRFGLATVK A BRAF 594-601 (600V)
B*27:05 202B RMFPNAPYL A WT-1 126-134 (Wilms tumor)
B*35:01 2307 MPFATPMEA A NY-ESO-1 94-102
H-2Db 1731 ATFKNWPFL A Murine Survivin 20-28
H-2Kb 351 HNTQYCNL A MAGEA5 5-12
H-2Kb 2311 TVSEFLKL A Murine Survivin 97-104
H-2Db 2199 FSNSTNDILI A VEGFR2/KDR fragment 1 614-624
H-2Db 695 Abu-Abu-L-Abu-LTVFL A Moloney murine sarcoma virus (MoMSV) GagL 85–93
 
H-2Db 1333 KVPRNQDWL A gp100 (pmel17) 25-33
H-2Db 1780 HCIRNKSVIL A hPSA
H-2Db 559 HCIRNKSVI A PSA 65-73
H-2Db 2695 ASMTNMELM A MC28 adpgk neoantigen
H-2Db 2755 AQLANDVVL A MC-38
H-2Db 2198 VILTNPISM A VEGFR2 400-408
H-2Db 3349 ASFRNLTHL A TPBG 258-266
H-2Db 231 CMTWNQMNL A WT1 235-243
H-2Db 202C RMFPNAPYL A WT-1 126-134 (Wilms tumor)
H-2Kb 2585 VGRNFTNL A mTERT
H-2Kb 2754 SIIVFNLL A MC-38
H-2Kb 3373 SDYYFSWL A muFAP? 289-296
H-2Kb 3376 SKYVFENV A Mybpc2 295-302
H-2Kb 185 SVYDFFVWL A Tyrosinase related protein-2 180-188
H-2Kd 814 EYILSLEEL A GPC3 298-306 
H-2Kd 343 TYVPANASL A Neu/Her-2/Erbb2 proto-oncoprotein 66-74
H-2Kd 275 DYWGQGTEL A Surface IgG (sA20-Ig) of A20 106-114
H-2Kd 485 AYIDFEMKI A SART3 315-323
H-2Kd 3381 SYMLQALCI A TNPO3
H-2Kk 825 FETFEAKI A T3H 104-111
H-2Ld 150 LPYLGWLVF A Tumour Antigen P815 35-43

 

(back to top)

 

Chlamydia

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 334 RLNMFTPYI A Chlamydia trachomatis MOMP 258-266

 

 

(back to top)

 

CMV


Publications citing CMV Pentamers

Case Studies of Customer Research into CMV

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 739 VTEHDTLLY A HCMV pp50 245-253
A*01:01 266 YSEHPTFTSQY A HCMV pp65 363-373
A*02:01 008 NLVPMVATV S HCMV pp65 495-504
A*02:01 1598 VLAELVKQI A HCMV IE1 81-89
A*02:01 2205 MLNIPSINV A pp65 120-128
A*02:01 144 VLEETSVML A HCMV IE1 316-324 (UL123)
A*03:01 1599 KLGGALQAK A HCMV IE1 184-192
A*24:02 414 QYDPVAALF A HCMV pp65 341-349
A*24:02 380 VYALPLKML A HCMV pp65 113-121
A*24:02 3390 AYAQKIFKI A CMV IE-1 248-256
B*07:02 308 RPHERNGFTVL A HCMV pp65 265-275
B*07:02 045 TPRVTGGGAM S HCMV pp65 417-426
B*08:01 127 ELRRKMMYM A IE1 199-207
B*08:01 3391 ELKRKMIYM A CMV IE-1 199-207 (R/L Position 3, M/I Position 7)
B*35:01 114 IPSINVHHY A HCMV pp65 123-131
H-2Db 2313 HGIRNASFI A MCMV m45 985-993
H-2Dd 278 AGPPRYSRI A MCMV m164 257-265
H-2Dd 2167 LGPISGHVL A pp65 15-23
H-2Kb 1915 TVYGFCLL A MCMV M139 419-426
H-2Kb 3413 VIDAFSRL A MCMV M141 15-23
H-2Kd 3412 CYYASRTKL A MCMV m145 451-459
H-2Ld 021 YPHFMPTNL S MCMV IE1 168-176

 

(back to top)

 

EBV


Publications citing EBV Pentamers
Case Studies of Customer Research into EBV

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 042 CLGGLLTMV S EBV LMP-2 426-434
A*02:01 001 GLCTLVAML S EBV BMLF-1 259-267
A*02:01 666 FLYALALLL A EBV LMP-2 356-364
A*02:01 409 YLLEMLWRL A EBV LMP-1 125-133
A*02:01 2292 FLDKGTYTL A EBV BALF-4 276–284
A*02:01 462 YVLDHLIVV A BRLF1 109–117
A*02:01 410 YLQQNWWTL A LMP1 159-167
A*02:01 1616 LLDFVRFMGV A EBV EBNA-3C 284-293
A*02:01 872 TLDYKPLSV A EBV BMRF1 208-216
A*03:01 727 RLRAEAQVK A ENV EBNA 3A 603–611
A*03:01 1838 RVRAYTYSK A BRLF1
A*11:01 199 IVTDFSVIK A EBV EBNA-4 416-424
A*11:01 508 SSCSSCPLSK A EBV LMP-2 340-349
A*11:01 639 ATIGTAMYK A EBV BRLF1 134-142
A*11:01 726 AVFDRKSDAK A EBNA3B 399-408
A*24:02 420 TYGPVFMCL A EBV LMP-2 419-427
A*24:02 648 PYLFWLAAI A EBV LMP2 131-139
A*24:02 683 TYGPVFMSL A EBV LMP2 419–427
B*07:02 044 RPPIFIRRL S EBV EBNA-3A 247-255
B*07:02 2305 QPRAPIRPI A EBV EBNA-3C 881-889
B*07:02 647 RPQGGSRPEFVKL A EBV BMRF1 116-128
B*08:01 073 FLRGRAYGL S EBV EBNA-3A 193-201
B*08:01 190 RAKFKQLL S EBV BZLF-1 190-197
B*08:01 489 QAKWRLQTL A EBV EBNA3A 158-166
B*35:01 399 EPLPQGQLTAY A EBV BZLF-1 54-64
B*35:01 3033 HPVAEADYFEY A EBV EBNA-1 407-417(4A)
B*35:01 107 YPLHEQHGM A EBV EBNA-3A 458-466
B*40:01 692 IEDPPFNSL A EBV LMP2 200-208

 

(back to top)

 

HBV


Publications citing HBV Pentamers
Case Studies of Customer Research into Hepatitis

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 032 FLLSLGIHL S HBV polymerase 573-581
A*02:01 027 FLLTRILTI S HBV envelope 183-191
A*02:01 023 FLPSDFFPSV S HBV core antigen 18-27
A*02:01 028 GLSPTVWLSV A HBV surface antigen 185-194
A*02:01 031 WLSLLVPFV S HBV surface antigen 172-181
A*02:01 283 FLPSDFFPSI A HBV core 18-27 (subtype ADR4)
A*02:01 2829 KLHLYSHPI A Pol 502-510
A*11:01 377 YVNVNMGLK A HBV core antigen 88-96
A*24:02 378 EYLVSFGVW A HBV core 117-125
A*24:02 413 KYTSFPWLL A HBV polymerase 756-764
H-2Kb 422 ILSPFLPLL A HBV surface antigen 208-216
H-2Kb 1431 MGLKFRQL A HBV core 93-100
H-2Kb 477 VWLSVIWM A HBV Surface antigen 190-197
H-2Ld 129 IPQSLDSWWTSL S HBV surface antigen 28-39

 

(back to top)

 

HCV


Publications citing HCV Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 740 ATDALMTGY A HCV NS3 1435-1443
A*01:01 1066 ATDALMTGF A HCV NS3 1436-1444
A*02:01 003 CINGVCWTV S HCV NS3 1073-1081
A*02:01 002 DLMGYIPAV S HCV core 132-140
A*02:01 040 KLVALGINAV S HCV NS3 1406-1415
A*02:01 491 DLMGYIPLV A HCV core 132-140
A*02:01 4 YLLPRRGPRL A HCV core 35-44
A*02:01 1094 GLQDCTMLV A HCV NS5B 2727-2735
A*02:01 242 KLSGLGINAV A HCV NS3 1406-1415
A*02:01 172 LLFNILGGWV A HCV NS4b 1807-1816
A*02:01 36 VLSDFKTWL A HCV NS5a 1987-1995 
A*02:01 858 CVNGVCWTV A HCV NS3 1073-1081
A*02:01 037 ALYDVVTKL A HCV NS5b 2594-2602
A*02:01 778 GLSRYVARL A HCV Pol 455-463
A*03:01 035 RVCEKMALY S HCV NS5B 2588-2596
A*24:02 415 AYSQQTRGL A HCV NS3 1031-1039
B*07:02 742 GPRLGVRAT A HCV core 41-49
B*07:02 845 DPRRRSRNL A HCV core 111-119
B*08:01 721 HSKKKCDEL A HCV NS3 1395-1403
B*27:05 871 ARMILMTHF A NS5B 2841-2849
B*35:01 565 HPNIEEVAL A HCV NS3 1359-1367
B*35:01 942 CPNSSIVY A HCV E1 207-214
B*40:01 939 REISVPAEIL A HCV NS5a 2266-2275
H-2Db 791 GAVQNEVTL A HCV NS3 1629-1637

 

(back to top)

 

HIV/SIV


Publications citing HIV Pentamers
Case Studies of Customer Research into HIV

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 084 ILKEPVHGV S HIV-1 RT 476-484
A*02:01 246 KLTPLCVTL A HIV-1 env gp120 90-98
A*02:01 010 SLYNTVATL S HIV-1 gag p17 76-84
A*02:01 174 TLNAWVKVV A HIV-1 gag p24 19-27
A*02:01 430 GLADQLIHL A HIV-1 Vif 101-109
A*02:01 799 LTFGWCFKL A HIV-1 Nef 137-145
A*02:01 1240 ALVEMGHHA A HIV Vpu 66-74
A*02:01 1147 FLGKIWPS A Gag 433-440
A*02:01 1244 NVWATHACV A HIV Env gp 67-7
A*02:01 1241 RTLNAWVKV A HIV Gag 150-158
A*02:01 3401 SLFNTVATL A HIV gag 77-85
A*02:01 1537 SLLNATAIAV A HIV env 816-825
A*02:01 3402 SLVKHHMYI A HIV Vif 23-31
A*02:01 3403 VIYHYVDDL A HIV Pol
A*03:01 109 QVPLRPMTYK S HIV-1 nef 73-82
A*03:01 194 RLRPGGKKK S HIV-1 gag p17 19-27
A*03:01 1496 AIFQSSMTK A HIV pol 325-333
A*11:01 1486 AVDLSHFLK A HIV nef 84-92
A*11:01 1686 ACQGVGGPGHK A HIV gag p24
A*24:02 419 RYLKDQQLL A HIV-1 gag gp41 67-75
A*24:02 411 RYPLTFGWCY A HIV-1 Nef 134-143
A*24:02 1805 RYLRDQQLL A HIV env
A*24:02 3238 RYPLTFGW A HIV nef
A*24:02 3099 RYPLTFGWCF A HIV NEF 143-152
A*29:02 3392 LYNTVATLY A HIV gag 79-86
A*29:02 3395 SFDPIPIHY A HIV env 216-224
A*29:02 3396 SFNCRGEFFY A HIV env 382-391
B*07:02 196 IPRRIRQGL A HIV-1 env gp120 848-856
B*07:02 257 TPGPGVRYPL S HIV-1 nef 128-137
B*07:02 877 GPGHKARVL A HIV gag p24 223–231
B*08:01 193 FLKEKGGL S HIV-1 nef 90-97
B*08:01 195 GEIYKRWII A HIV-1 gag p24 261-269
B*08:01 879 EIYKRWII A HIV p24  gag 128-135
B*08:01 1536 YLKDQQLL A Env 586-593
B*15:01 1072 RLRPGGKKKY A HIV-1 p17 20-29
B*27:05 294 KRWIILGLNK A HIV-1 gag p24 265-274
B*27:05 874 KRWIIMGLNK A HIV-1 Gag p24 263-272
B*27:05 2306 GRAFVTIGK A HIV-1 gp100 103-111
B*35:01 255 NPDIVIYQY A HIV-1 RT 330-338
B*35:01 255 NPDIVIYQY A HIV-1 HIV-1 RT 328-336
B*35:01 1211 VPLDEDFRKY A HIV-1 HIV-1 RT 273-282
B*40:01 840 KEKGGLEGL A HIV-1 Nef 92-100
H-2Db 719 AAVKNWMTQTL A SIV gag
H-2Dd 177 RGPGRAFVTI A HIV-1 IIIB gp120 318-327
H-2Dd 1684 IGPGRAFYA A HIV-1 US4 gp120 318-326
H-2Kd 176 AMQMLKETI A HIV-1 gag p24 199-207
H-2Kd 403 AMQMLKDTI A HIV gag p24 197-205
Mamu-A*01 1110 CTPYDINQM A SIV Gag 181-189
Mamu-A*02 1111 YTSGPGIRY A SIV Nef 159-167
Mamu-A*02 1112 GSENLKSLY A SIV Gag 71-79

 

(back to top)

 

HPV

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 095 YMLDLQPETT S HPV 16 E7 11-20
A*02:01 2312 MLDLQPETT A HPV 16 E7 12-20
A*02:01 658 KLPQLCTEL A HPV 16 E6 18-26
A*03:01 2064 KLCLRFLSK A HPV 33 E6 64-72
A*11:01 2067 NTLEQTVKK A HPV 33E6 86-94
A*24:02 3240 VYDFAFRDL A HPV16 E6
B*07:02 2065 KPTLKEYVL A HPV 33 E7 5-13
H-2Db 502H RAHYNIVTF A HPV 16 E7 49-57
H-2Db 3404 AGVDNRECI A HPV L1 165-173
H-2Kb 2560 EVYDFAFRDL A HPV E6 48-57

 

(back to top)

 

HSV

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 1152 VLMIKALEL A Non muscle Myosin-9 741-749
A*02:01 1153 QLFNHTMFI A Non-muscle Myosin 478-486
A*02:01 3406 QMARLAWEA A 1116-1124
H-2Db 3405A  AGPHNDMEI A HSV p56 487-495
H-2Dd 3405B AGPHNDMEI A HSV p56 487-495
H-2Kb 188 SSIEFARL A HSV-1 gp B 498-505
H-2Kd 3407 TYWPVVSDI A 207-215

 

(back to top)

 

HTLV


Publications citing HTLV Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 200 LLFGYPVYV A Human T-cell lymphotropic virus-1 (HTLV-1) tax 11-19
A*02:01 2309 AVLDGLLSL A HTLV bZIP factor 42-50
A*02:01 3408 GLLSLEEEL A bZIP factor 26-34
A*24:02 1043 SFHSLHLLF A HTLV Tax 301-309
B*07:02 3400 LPVSCPEDL A bZIP factor 10-18

 

(back to top)

 

Influenza


Publications citing Influenza Pentamers
Case Studies of Customer Research into Influenza

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 076 CTELKLSDY A Influenza A (PR8) NP 44-52
A*01:01 540 VSDGGPNLY A Influenza A PB1 591-599
A*02:01 007 GILGFVFTL S Influenza A MP 58-66
A*02:01 2295 ILGFVFTLTV A Influenza A MP 59-68
A*02:01 3409 KLGEFYNQMM A Flu BNP 85-94 (Influenza B)
A*03:01 077 ILRGSVAHK A Influenza A (PR8) NP 265-274
A*11:01 1722 KSMREEYRK A Influenza A MP2 70-78
A*11:01 1720 RMVLASTTAK A Influenza A MP1 178-187
A*11:01 1513 SIIPSGPLK A Influenza A MP 13-21
B*07:02 1743 QPEWFRNVL A Influenza A PB1 329-337
B*07:02 1744 SPIVPSFDM A Influenza A NP 473-481
B*27:05 463 SRYWAIRTR A Influenza A NP 383-391
H-2Db 009 ASNENMDAM S Influenza A (NT60) NP 366-374
H-2Db 119 ASNENMETM S Influenza A (PR8) NP 366-374
H-2Db 3410 SCLENFRAYV A Influenza A polymerease PA 224-233
H-2Db  120 SSLENFRAYV A Influenza A (PR8) Polymerase acidic protein 224-233
H-2Kd 240 IYSTVASSL A Influenza A HA 533-541
H-2Kd 098 TYQRTRALV S Influenza A (PR8) NP 147-155

 

(back to top)

 

JC Virus

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 611 ILMWEAVTL A VP1 100-108
A*02:01 610 SITEVECFL A VP1 36-44

 

(back to top)

 

LCMV


Publications citing LCMV Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 2308 ALPHIIDEV A LCMV envelope gp 10-18
A*02:01 2310 YLVSIFLHL A LCMV envelope gp 447-455
A*02:01 3411 SLNQTVHSL A NP 69-77
H-2Kb 2076 ISHNFCNL A LCMV GP 118-125
H-2Db 070 FQPQNGQFI S LCMV NP 396-404
H-2Db 069 KAVYNFATC S LCMV GP1 33-41
H-2Db 186 SGVENPGGYCL A LCMV GP 276-286
H-2Db 142 KAVYNFATM A gp33 (C9M)

 

(back to top)

 

Listeria


Publications citing Listeria Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
H-2Kd 178 GYKDGNEYI A Listeria monocytogenes Listeriolysin 91-99

 

(back to top)

 

Malaria


Publications citing Malaria Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*02:01 314 YLNKIQNSL A Plasmodium falciparum CSP 334-342
H-2Db 2697 SQLLNAKYL A Plasmodium berghei ANKA acid phosphatase 40-48
H-2Kd 376 SYIPSAEKI A Plasmodium berghei CSP 252-260
H-2Kd 2290 SYVPSAEQI A Plasmodium CSP
H-2Kd  771 YYIPHQSSL A Plasmodium falciparum Liver stage antigen 1671-1679 

 

(back to top)

 

Minor Histocompatibility Antigen


Publications citing miHAg Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
A*01:01 652 IVDCLTEMY A DRRFY (1521-1529))
A*02:01 581 RTLDKVLEV A miHAg HA-8
A*02:01 175 FIDSYICQV A miHAg H-Y (human SMCY) 311-319
A*02:01 473 VLHDDLLEA A Minor Histocompatibility Antigen HA-1 137-145
A*02:01 395 YIGEVLVSV A HA-2
B*07:02 1113 SPSVDKARAEL A MiHAg SMCY 1041-1051
H-2Db 328 KCSRNRQYL A miHAg SMCY 738-746
H-2Db 327 WMHHNMDLI S miHAg UTY 246-254
H-2Kk 269 TENSGKDI A SMCY 1332-1339

 

(back to top)

 

Model Antigen


Publications citing Model Antigen Pentamers

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
H-2Kb 093 SIINFEKL S Ovalbumin 257-264
H-2Kb 908 KVVRFDKL A Ovalbumin (subdominant) 55-62
H-2Kb 1803 SIYRYYGL A Synthetic variant of VSV Nucleoprotein 498–505
H-2Kb 562 LTFNYRNL A Histocompatibility antigen 60 39-46 
H-2Kd 198 HYLSTQSAL A Enhanced Green Fluorescent Protein (eGFP) 200-208
H-2Ld 074 TPHPARIGL S E. coli beta-galactosidase 876-884

 

(back to top)

 

MuLV

 

 ALLELE PEPTIDE CODE PEPTIDE SEQUENCE Stock/
Available
EPITOPE ORIGIN
H-2Kb 828 KSPWFTTL A MuLV env 622-629
H-2Ld 398 SPSYVYHQF A